Ibrance (palbociclib) - Drug Insight and Market Forecast - 2030

Ibrance (palbociclib) - Drug Insight and Market Forecast - 2030

  • August 2020 •
  • 80 pages •
  • Report ID: 5865971 •
  • Format: PDF
Overview
“Ibrance– Drug Insight and Market Forecast — 2030” report outlays comprehensive insights of the product indicated for the treatment of Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2?) Advanced or Metastatic Breast Cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women; or fulvestrant in women with disease progression following endocrine therapy. A detailed picture of the Ibrance in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, United Kingdom) and Japan, for the study period 2017–2030 is provided in this report. The report contains a detailed description of the product covering mechanism of action, dosage and administration, route of synthesis and pharmacological studies, also including product marketed details, regulatory milestones and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Ibrance is an oral inhibitor of CDKs 4 and 6,6 which are key regulators of the cell cycle that trigger cellular progression. In the US, Ibrance is indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy. In April 2019, the US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for Ibrance (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Ibrance currently is approved in more than 90 countries and has been prescribed to more than 200,000 patients globally.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug marketed details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Ibrance (palbociclib).
• The report contains historical and forecasted sales for Ibrance (palbociclib) till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
• The report also features the SWOT analysis with analyst insights and key findings of Ibrance (palbociclib).

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis ’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Ibrance (palbociclib) Analytical Perspective
• In-depth Ibrance (palbociclib) Market Assessment
This report provides a detailed market assessment of Ibrance (palbociclib) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

• Ibrance (palbociclib) Clinical Assessment
The report provides the clinical trials information of Ibrance (palbociclib) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Ibrance (palbociclib) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Ibrance (palbociclib) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other approved products for the disease are giving market competition to Ibrance (palbociclib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Ibrance (palbociclib).
• Our in-depth analysis of the sales data of Ibrance (palbociclib) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Ibrance (palbociclib) in the market.

Key Questions
• What is the prescribed dosage and strengths of Ibrance (palbociclib) are available in the market?
• What are the common adverse reactions or side effects of Ibrance (palbociclib)?
• What is the product type, route of administration and mechanism of action of Ibrance (palbociclib)?
• What are the chemical specifications of Ibrance (palbociclib)?
• How are the clinical trials diversified on the basis of the trial status?
• What is the history of Ibrance (palbociclib), and what is its future?
• What are the marketed details of Ibrance (palbociclib) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• How many patents have been granted to Ibrance (palbociclib) and when these patents will get expire?
• What are the pros (benefits) and cons (disadvantages) of Ibrance (palbociclib)?
• In which countries Ibrance (palbociclib) got approval and when it gets launched?
• What are the clinical trials are currently ongoing for Ibrance (palbociclib)?
• How the safety and efficacy results determined the approval of Ibrance (palbociclib)?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Ibrance (palbociclib) development?
• What are the key designations that have been granted to Ibrance (palbociclib)?
• What is the historical and forecasted market scenario of Ibrance (palbociclib)?
• How is the market trend of Ibrance (palbociclib) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
• What are the other approved products available and how these are giving competition to Ibrance (palbociclib)?
• Which are the late-stage emerging therapies under development for the treatment of the indicated condition?